Enox Biopharma, Inc. Announces Publication of Scientific Discoveries

Jan 05, 2010, 09:00 ET from Enox Biopharma, Inc.

VANCOUVER, British Columbia, Jan. 5 /PRNewswire/ -- A prestigious peer-review journal will publish an article in its January 2010 edition outlining a Vancouver BC based biomedical technology company's solution to the growing problem of hospital patients acquiring bacterial infections.

The article about Enox Biopharma's self-sterilizing technology for catheters (patent pending) was accepted for publication in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology and one of the most prominent publications in the field.

Professor Yossef Av-Gay and his team demonstrated the ability of Enox's Foley gaseous nitric oxide-impregnated catheters to prevent common bacterial infections. "Our approach to this problem required ingenuity, technology and common sense, and a lot of strong, tested science to develop a medical and technological solution to a chronic problem in today's hospitals," Dr. Av-Gay, Enox Biopharma's president, explained.

The paper's authors describe and detail Enox Biopharma's nitric oxide gas impregnation technology and its approach to prevent the colonization of catheters by urinary tract infection associated bacteria.

"Nitric oxide gas is a naturally produced free radical with proven bactericidal effect. Its potential impact in preventing infection without the use of antibiotic applications or coatings is significant," Dr. Av-Gay said, adding, "There is limited risk of patients developing resistance to its antibacterial properties."

In the manuscript, the authors describe the process in which Foley urinary catheters were impregnated with gaseous nitric oxide. Using Enox's technology, the catheters released molecules of nitric oxide slowly and steadily over a 14-day period. The charged catheters became antiseptic, able to prevent bacterial colonization and biofilm formation on their luminal and exterior surfaces. The paper reports the finding that nitric oxide impregnated catheters inhibited the growth of Escherichia coli within the surrounding media.

The study is entitled "The slow release of Nitric Oxide from charged catheter and its effect on biofilm formation by Escherichia coli".

About Enox Biopharma Inc.

Enox Biopharma is an emerging biotechnology company engaged in the development of products and process that leverage the robust bactericidal effects of gNO impregnated into medical devices. The company is pursuing dynamic strategies to bring these new biomedical technology breakthroughs to a global market. Infections caused by urinary catheters cost the United States healthcare system over US$1 billion per year.

For more information, please contact:


    Darryl K. Saunders
    Enox Biopharma, Inc.
    604.637.9744 phone

    888.224.7259 fax
    info@enoxbiopharma.com
    www.enoxbiopharma.com

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

Safe Harbor Statement

This press release contains certain forward-looking statements. Forward-looking statements may include our statements regarding our goals, beliefs, strategies, objectives, plans, including product and service developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from those contemplated by the forward-looking statements. Further information on potential factors that could affect our business is described under the heading "Risks Related to Our Business" in Part I, Item 1, "Description of Business" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in our registration statement on Form S-1 no. 333-154763, which was declared effective on October 31, 2008. Except as otherwise required by law, Enox Biopharma, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE Enox Biopharma, Inc.



RELATED LINKS

http://www.enoxbiopharma.com